I am a
Home I AM A Search Login

Papers of the Week

2021 Jan

Open Forum Infect Dis



Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced Patients.


Schafer JJ, Pandit NS, Cha A, Huesgen E, Badowski M, Sherman EM, Cocohoba J, Shimada A, Keith SW
Open Forum Infect Dis. 2021 Jan; 8(1):ofaa625.
PMID: 33511239.


Switching antiretroviral therapy (ART) in people with HIV (PWH) can influence their risk for drug-drug interactions (DDIs). The purpose of this study was to assess changes in the incidence and severity of DDIs among PWH who switched their ART to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).